Ara Metjian

1.9k total citations · 1 hit paper
40 papers, 1.2k citations indexed

About

Ara Metjian is a scholar working on Immunology, Hematology and Genetics. According to data from OpenAlex, Ara Metjian has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 19 papers in Hematology and 17 papers in Genetics. Recurrent topics in Ara Metjian's work include Complement system in diseases (23 papers), Renal Diseases and Glomerulopathies (14 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers). Ara Metjian is often cited by papers focused on Complement system in diseases (23 papers), Renal Diseases and Glomerulopathies (14 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (11 papers). Ara Metjian collaborates with scholars based in United States, Canada and Austria. Ara Metjian's co-authors include Javier de la Rubia, Spero R. Cataland, Marie Scully, Flora Peyvandi, Filip Callewaert, Johanna A. Kremer Hovinga, Paul Coppo, Katerina Pavenski, Hilde De Winter and Paul Knöbl and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Blood.

In The Last Decade

Ara Metjian

33 papers receiving 1.2k citations

Hit Papers

Caplacizumab Treatment for Acquired Thrombotic Thrombocyt... 2019 2026 2021 2023 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
    2019 602 citations Marie Scully, Spero R. Cataland et al. profile →

Peers

Ara Metjian
Aishwarya Ravindran United States
Kenji Soejima Japan
Saskia Langemeijer Netherlands
Bill Giannakopoulos Australia
Fabien B. Vincent Australia
Robert Biesen Germany
Susan A. Boackle United States
María Luz Sánchez Spain
Ken�ichi Sekita Japan
P. A. Dyer United Kingdom
Aishwarya Ravindran United States
Ara Metjian
Citations per year, relative to Ara Metjian Ara Metjian (= 1×) peers Aishwarya Ravindran

Countries citing papers authored by Ara Metjian

Since Specialization
Citations

This map shows the geographic impact of Ara Metjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ara Metjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ara Metjian more than expected).

Fields of papers citing papers by Ara Metjian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ara Metjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ara Metjian. The network helps show where Ara Metjian may publish in the future.

Co-authorship network of co-authors of Ara Metjian

This figure shows the co-authorship network connecting the top 25 collaborators of Ara Metjian. A scholar is included among the top collaborators of Ara Metjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ara Metjian. Ara Metjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hansen, Kirk C., et al.. (2025). Proteomics of arterial thrombi in acute limb ischemia. Journal of Thrombosis and Thrombolysis. 58(7). 866–881.
2.
3.
Scully, Marie, Javier de la Rubia, Ara Metjian, et al.. (2022). Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study. Journal of Thrombosis and Haemostasis. 20(12). 2810–2822. 14 indexed citations
4.
Peyvandi, Flora, Spero R. Cataland, Marie Scully, et al.. (2021). Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances. 5(8). 2137–2141. 50 indexed citations
5.
Josephson, Cassandra D., Stuart L. Goldstein, David J. Askenazi, et al.. (2021). Safety and tolerability of solvent/detergent‐treated plasma for pediatric patients requiring therapeutic plasma exchange: An open‐label, multicenter, postmarketing study. Transfusion. 62(2). 396–405. 6 indexed citations
6.
Peyvandi, Flora, Spero R. Cataland, Marie Scully, et al.. (2021). INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA. Hematology Transfusion and Cell Therapy. 43. S46–S47.
7.
Yuan, Xuan, Jia Yu, Gloria F. Gerber, et al.. (2020). Ex vivo assays to detect complement activation in complementopathies. Clinical Immunology. 221. 108616–108616. 10 indexed citations
8.
Metjian, Ara, et al.. (2020). Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura. Therapeutic Advances in Hematology. 11. 154194680–154194680. 33 indexed citations
9.
Cataland, Spero R., Marie Scully, Flora Peyvandi, et al.. (2019). Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood. 134(Supplement_1). 4908–4908.
10.
Knoebl, Paul, Spero R. Cataland, Flora Peyvandi, et al.. (2019). Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis. 18(2). 479–484. 41 indexed citations
11.
Metjian, Ara, et al.. (2018). A rare CALR variant mutation and a review of CALR in essential thrombocythemia. Journal of Thrombosis and Thrombolysis. 45(3). 457–462. 2 indexed citations
12.
Scully, Marie, Spero R. Cataland, Flora Peyvandi, et al.. (2017). Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood. 130(Suppl_1). LBA–1. 16 indexed citations
13.
Metjian, Ara, Yvette C. Tanhehco, Nicole A. Aqui, et al.. (2015). The thrombotic microangiopathy Registry of North America: A United States multi‐institutional TMA network. Journal of Clinical Apheresis. 31(5). 448–453. 7 indexed citations
14.
Nipp, Ryan David, Aaron Philip Mitchell, Allyson M. Pishko, & Ara Metjian. (2014). Waldenström Macroglobulinemia in Hepatitis C: Case Report and Review of the Current Literature. Case Reports in Oncological Medicine. 2014. 1–7. 5 indexed citations
15.
Patil, Avinash S., Sarah K. Dotters‐Katz, Ara Metjian, Allison James, & Geeta K. Swamy. (2013). Use of a Thrombopoietin Mimetic for Chronic Immune Thrombocytopenic Purpura in Pregnancy. Obstetrics and Gynecology. 122(2). 483–485. 29 indexed citations
16.
Lee, Grace M., Wei Duan‐Porter, & Ara Metjian. (2012). Acquired, non‐amyloid related factor X deficiency: review of the literature. Haemophilia. 18(5). 655–663. 25 indexed citations
17.
18.
Metjian, Ara, Suman L. Sood, Adam Cuker, et al.. (2009). Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia. 15(4). 918–925. 28 indexed citations
19.
Metjian, Ara & Charles S. Abrams. (2007). New insights and therapeutics for immune-mediated thrombocytopenia. Expert Review of Cardiovascular Therapy. 6(1). 71–84. 1 indexed citations
20.
Metjian, Ara, et al.. (1999). Agonists Cause Nuclear Translocation of Phosphatidylinositol 3-Kinase γ. Journal of Biological Chemistry. 274(39). 27943–27947. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aishwarya Ravindran Breakdown of academic impact, for papers by Kenji Soejima Breakdown of academic impact, for papers by Saskia Langemeijer Breakdown of academic impact, for papers by Bill Giannakopoulos Breakdown of academic impact, for papers by Fabien B. Vincent Breakdown of academic impact, for papers by Robert Biesen Breakdown of academic impact, for papers by Susan A. Boackle Breakdown of academic impact, for papers by María Luz Sánchez Breakdown of academic impact, for papers by Ken�ichi Sekita Breakdown of academic impact, for papers by P. A. Dyer
Rankless by CCL
2026